It’s that time of year once again: Instagram and Twitter will adopt a light shade of pink, companies will adorn their products with the ubiquitous pink ribbon, all to remind us of Breast Cancer Awareness Month. To a breast cancer scientist such as myself, October always brings out ambiguous emotions. On one side, it serves as a reminder of all the great research and results that we have achieved. Statistics show that things are getting better for many women, as mortality rates have halved in the last 20 years. October also prompts many of us to remember that there is nothing better than prevention when talking about breast cancer. Early screening measures have revolutionised outcomes for women; it’s very likely that almost 50% of the lives that were saved depended on catching the cancer earlier.
The other major breakthrough was the development of targeted therapies for the most common molecular subtype of breast cancer (luminal subtypes) accounting for 70% of all new breast cancers. Years of rigorous clinical trials with these drugs have helped reduce the number of women that develop secondary disease (metastatic) – the consequence of the primary breast cancer cells spreading to other organs. This is where my ambivalence stems from; far too many women still have their breast cancer relapse. Outside of the beautiful pink narrative which Samantha King – author of Pink Ribbons, Inc: Breast Cancer and the Politics of Philanthropy – called “the tyranny of cheerfulness”, breast cancer remains the second largest cause of cancer-related deaths in women. (more…)